Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat

Gene Therapy

Volumn 6, Issue 12, 1999, Pages 1936-1951

  Connor, B ^a   Kozlowski, D A ^a   Schallert, T ^b   Tillerson, J L ^b   Davidson, B L ^c   Bohn, M C ^a,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d CMIER   (United States)

Author keywords

Adenoviral vector; Aging; Gene therapy; Neurodegeneration; Parkinson's disease

Indexed keywords

6 HYDROXYDOPA; AMPHETAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; TYROSINE 3 MONOOXYGENASE; VIRUS VECTOR;

ADENOVIRUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; MALE; NERVE PROJECTION; NONHUMAN; ONCOGENE C FOS; PARKINSON DISEASE; PERIKARYON; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ADENOVIRIDAE; AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DOPAMINE; DOPAMINE AGENTS; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, FOS; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; INJECTIONS, INTRAVENTRICULAR; MALE; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RANDOM ALLOCATION; RATS; RATS, INBRED F344; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

ADENOVIRIDAE; ANIMALIA; PARKINSONIA;

EID: 0033374356     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301033     Document Type: Article

References (93)

1. Bohn MC, Choi-Lundberg DL. Neurotrophic factor gene therapy for neurodegenerative disease. Gene Ther Molec Biol 1998; 1: 265-277.
2. Choi-Lundberg DL, Bohn MC. Applications of gene therapy to neurological diseases and injuries. In: Quesenberry PJ, Stein GS, Forget B, Weissman S (eds). Stem Cell Biology find Gene Therapy. Wiley-Liss: New York, 1998, pp 503-553.
3. Connor B, Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res 1998; 27: 1-39.
4. Lindsay RM. Neurotrophic growth factors and neurodegenerative diseases: therapeutic potential of the neurotrophins and ciliary neurotrophic factor. Neurobiol Aging 1994; 15: 249-251.
5. Bohn MC, Choi-Lundberg DL. Gene therapies for Parkinson's disease. In: Chiocca EA, Breakfield XO (eds). Gene Therapy for Neurologícal Disorders and Brain Tumors. Humana Press: Totowa, NJ, 1997, pp 377-395.
6. Unsicker K. GDNF: a cytokine at the interface of TGF-betas and neurotrophins. Cell Tiss Res 1996; 286: 175-178.
7. Krieglstein K, Suter-Crazzolara C, Unsicker K. Development of mesencephalic dopaminergic neurons and the transforming growth factor-beta superfamily. J Neural Transmis Suppl 1995; 46: 209-216.
8. Lin L-FH et al. A glial cell-line derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993; 260: 1130-1132.
9. Beck KD et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 1995; 373: 339-341.
10. Hoffer BJ et al. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 1994; 182: 107-111.
11. Kearns C, Gash D. GDNF protects nigral dopaminergic neurons against 6-hydroxydopamine in vivo. Brain Res 1995; 672: 104-111.
12. Tomac A et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995; 373: 335-339.
13. Sauer H, Rosenblad C, Bjorklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor beta-3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc Nat Acad Sci USA 1995; 92: 8935-8939.
14. Bowenkamp KE et al. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J Comp Neurol 1995; 355: 479-489.
15. Lapchak PA, Miller PJ, Collins F, Jiao S. Glial cell line-derived neurotrophic factor attenuates behavioral deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopaminc-lesioned adult rats: comparison of intraventricular and intranigral delivery. Neuroscience 1997; 78: 61-72.
16. Rosenblad C, Martinez-Serrano A, Bjorklund A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscice 1998; 82: 129-137.
17. Lindner MD et al. Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine deletions and Parkinsonian symptoms. Exp Neurol 1995; 132: 62-76.
18. Gash DM et al. Functional recovery in Parkinsonian monkeys treated with GDNF. Nature 1996; 380: 252-255.
19. Ghodsi A et al. Extensive beta-glucuronidase activity in murine central nervous system after adenovirus-mediated gene transfer to brain. Hum Gene Ther 1998; 9: 2331-2340.
20. Akli S et al. Transfer of a foreign gene into the brain using adenovirus vectors. Nat Genet 1993; 3: 224-228.
21. Bajocchi G, Feldman SH, Crystal RG, Mastrangeli A. Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors Nat Genet 1993; 3: 229-234.
22. Davidson BL et al. A model system for in vivo gene transfer into the central nervous system using an adenovirus vector. Nat Genet 1993; 3: 219-223.
23. Le Gal La Salle G et al. An adenovirus vector for gene transfer into neurons and glia in the brain. Science 1993; 259: 988-990.
24. Choi-Lundberg DL et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997; 275: 338-341.
25. Davidson BL, Bohn MC. Recombinant adenovirus: a gene transfer vector for study and treatment of CNS disease. Exp Neurol 1997; 144: 125-130.
26. Horellou P, Sabate O, Buc-Caron M-H, Mallet J. Adenovirus-mediated gene transfer to the central nervous system for Parkinson's disease. Exp Neurol 1997; 144: 131-138.
27. Choi-Lundberg DL et al. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp Neurol 1998; 154: 261-275.
28. Bilang-Bleuel A et al. Intrastriatal injection of an adenoviral vector expressing glial cell-line derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson's disease. Proc Natl Acad Sci USA 1997; 94: 8818-8823.
29. Mandel R, Spratt S, Snyder R, Leff S. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci 1997; 94: 14083-14088.
30. Bowenkamp K, Lapchak P, Hoffer B, Bickford P. Glial cell line-derived neurotrophic factor reverses motor impairment in 16-17 month old rats. Neurosci Lett 1996; 211: 81-84.
31. Hebert MA, Gerhardt GA. Behavioural and neurochemical effects of intranigral administration of glial cell line-derived neurotrophic factor on aged Fischer 344 rats. J Pharmacol Exp Ther 1997; 282: 760-768.
32. Lapchak P, Miller P, Jiao S. Glial cell line-derived neurotrophic factor induces the dopaminergic and cholinergic phenotype and increases locomotor activity in aged Fischer-344 rats. Neuroscience 1997; 77: 745-752.
33. Emerich DF et al. Alleviation of behavioral deficits in aged rodents following implantation of encapsulated GDNF-producing fibroblasts. Brain Res 1996; 736: 99-110.
34. Date I et al. GDNF administration induces recovery of the nigrostriatal dopaminergic system both in young and aged parkinsonian mice. NeuroReport 1998; 9: 2365-2369.
35. Zigmond M et al. Compensatory responses to partial loss of dopaminergic neurons: studies with 6-hydroxydopamine. In: Schneider J, Gupta M (eds). Current Concepts in Parkinson's Disease Research. Hogrefe and Huber: Göttingen, 1993, pp 99-140.
36. Demarest KT, Riegle GD, Moore KE. Characteristics of dopaminergic neurons in the aged male rat. Neuroendocrinology 1980; 31: 222-227.
37. Unnerstall JR, Long MM. Differential effects of the intraventricular administration of 6-hydroxydoparnine on the induction of type II beta-tubulin and tyrosine hydroxylase mRNA in the locus coeruleus of the aging Fischer 344 rat. J Comp Neurol 1996; 364: 363-381.
38. Schallert T. Aging-dependent emergence of sensorimotor dysfunction in rats recovered from dopamine sustained early in life. In: Joseph JA (ed). Central Determinants of Age-Related Decline in Motor Function. Annals of New York Academy of Science: New York, 1988, pp 108-119.
39. Bjorklund A, Rosenblad C, Winkler C, Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis 1997; 4: 186-200.
40. Ungerstedt U. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behavior. Acta Physiol Scand 1971; 82: 49-68.
41. Sauer H, Oertel WH. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994; 59; 401-415.
42. Liu FC, Graybiel AM, Dunnett SB, Braughman RW. Intrastriatal grafts derived from fetal striatal primordia. II. Reconstitution of cholinergic and dopaminergic systems. J Comp Neurol 1990; 295: 1-14.
43. Morgan JI, Curran T. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Ann Rev Neurosci 1991; 14: 421-451.
44. Cenci M et al. Dopaminergic transplants normalize amphetamine and apomorphine-induced Fos expression in the 6-hydroxy-dopamine lesioned striatum. Neuroscience 1992; 46: 943-957.
45. Labandeira-Garcia J et al. Time course of striatal changes induced by 6-hydroxydopamine lesion of the nigrostriatal pathway, as studied by combined evaluation of rotational behavior and striatal Fos expression. Exp Brain Res 1996; 108: 69-84.
46. Robertson HA, Peterson MR, Murphy K, Robertson GS. D1-dopamine receptor agonists selectively activate striatal c-fos independent of rotational behavior. Brain Res 1989; 503: 346-349.
47. Graybiel AM, Moratalla R, Robertson HA. Amphetamine and cocaine induces drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc Natl Acad Sci USA 1990; 87: 6912-6916.
48. Robertson GS, Vincenty SR, Fibiger HC. D1 and D2 dopamine receptors differentially regulate c-fos exprssion in striatonigral and striatopallidal neurons. Neuroscience 1992; 49: 285-296.
49. Paul ML, Graybiel AM, David JC, Robertson HA. D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease. J Neurosci 1992; 12: 3729-3742.
50. Konradi C, Cole RL, Heckers S, Hyman SE. Amphetamine regulates gene expression in rat striatum via transcription factor CREB. J Neurosci 1994; 14: 5623-5634.
51. Berretta S, Robertson HA, Graybiel AM. Dopamine and glutamine agonists stimulate neuron-specific expression of Fos-like protein in the striatum. J Neurophysiol 1992; 68: 767-777.
52. Matheson CR et al. Glial cell line-derived neurotrophic factor (GDNF) is a neurotrophic factor for sensory neurons: comparison with the effects of the neurotrophins. J Neurobiol 1997; 32: 22-32.
53. Byrnes AP, Rusby JE, Wood MJA, Charlton HM. Adenovirus gene transfer causes inflammation in the brain. Neuroscience 1995; 66: 1015-1024.
54. Bohn MC et al. Adenoviral-mediated transgene expression in non-human primate brain. Hum Gene Ther 1999; 10: 1175-1184.
55. Lawrence MS et al. Inflammatory responses and their impact on beta-galactosidase transgene expression following adenovirus vector delivery to the primate caudate nucleus. Gene Therapy 1999; 6: 1368-1379.
56. Martin D et al. Intranigral or intrastriatal injections of GDNF - effects on monoamine levels and behavior in rats. Euro J Pharmacol 1996; 317: 247-256.
57. Lapchak P et al. Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): preclinical development and application to the treatment of Parkinson's disease. Exp Neurol 1997; 145: 309-321.
58. Morgan D, Finch C. Dopaminergic changes in the basal ganglia: a generalized phenomenon of aging in mammals. Ann NY Acad Sci 1998; 515: 145-160.
59. Felter D et al. Age-related decline in the dopaminergic nigrostriatal system: the oxidative hypothesis and protective strategies. Ann Neurol 1992; 32: S133-S136.
60. Roth GS, Joseph JA. Cellular and molecular mechanisms of impaired dopaminergic function during aging. Ann NY Acad Sci 1994; 719: 129-135.
61. Hubble JP. Aging and the basal ganglia. Neurol Clin 1998; 16: 649-657.
62. Yu T et al. Expression of GDNF family receptor components during development: implications in the mechanisms of interaction. J Neurosci 1998; 18: 4684-4696.
63. Trupp M, Belluardo N, Funakoshi H, Ibanez CF. Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the adult rat CNS. J Neurosci 1997; 17: 3554-3567.
64. Glazner GW, Mu X, Springer JE. Localization of glial cell line-derived neurotrophic factor receptor alpha and c-ret mRNA in rat central nervous system. J Comp Neurol 1998; 391: 42-49.
65. Kirik D, Rosenblad C, Bjorklund A. Characterization of behavioral and neurodegeneration changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 1998; 153: 259-277.
66. Shults CW, Kimber T, Martin D. Intrastriatal injection of GDNF attenuates the effects of 6-hydroxydopamine. NeuroReport 1996; 7: 627-631.
67. Schwarting R, Huston J. The unilateral 6-hydroxydopamine lesion model in behavioral brain research analysis of functional deficits, recovery and treatments. Prog Neurobiol 1996; 50: 275-331.
68. Brass CA, Glick SD. Sex difference in drug-induced rotation in two strains of rats. Brain Res 1981; 223: 229-234.
69. Tillerson JL, Castro SL, Zigmond MJ, Schallert T. Motor rehabilitation of forelimb use in unilateral 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. Soc Neurosci Abstr 1998; 24: 1720.
70. Naldini L et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93: 11382-11388.
71. Kafri T et al. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997; 17: 314-317.
72. Kaplitt MG et al. Long-term expression and phenotypic correction using adeno-associafed virus vectors in the mammalian brain. Nat Genet 1994; 8: 148-154.
73. McCown TJ et al. Differential and persistent expression pattern of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res 1996; 713: 99-107.
74. Lo WD et al. Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression. Hum Gene Ther 1999; 10: 201-213.
75. Yang Y et al. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994; 7: 362-369.
76. Fang B et al. Lack of persistence of E1-recombinant adenoviral vectors containing a temperature-sensitive E2a mutation in immunocompetent mice and hemophilia B dogs. Gene Therapy 1996; 3: 217-222.
77. Amalfitano A, Chamberlain JS. Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy. Gene Therapy 1997; 4: 258-263.
78. Amalfitano A, Begy CR, Chamberlain JS. Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc Natl Acad Sci USA 1996; 93: 3352-3356.
79. Amalfitano A et al. Production and characterization of improved adenovirus vectors with E1, E2b and E3 genes deleted. J Virol 1998; 72: 926-933.
80. Crouzet J et al. Recombinational construction in Escherichia coli of infectious adenoviral genomes. Proc Natl Acad Sci USA 1997; 94: 1414-1419.
81. Armentano D et al. Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum Gene Ther 1995; 6: 1343-1353.
82. Armentano D et al. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J Virol 1997; 71: 2408-2416.
83. Parks RJ et al. A helper-dependent adenovirus vector system: removal of helper virus by cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996; 93: 13565-13570.
84. Kochanek S et al. A new adenoviral vector: replacement of all viral coding sequences with a 26 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci USA 1996; 93: 5731-5736.
85. Fisher KJ et al. Recombinant adenovirus deleted of all viral genes for gene therapy therapy of cystic fibrosis. Virology 1996; 217: 11-22.
86. Morsy MA et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 1998; 95: 7866-7871.
87. Schallert T, Jones TA, Norton DA. A clinically relevant unilateral rat model of Parkinsonian akinesia. J Neural Transplant Plast 1992; 3: 332-333.
88. Schallert T, Lindner MD. Rescuing neurons from trans-synaptic degeneration after brain damage: helpful, harmful, or neutral in recovery of function? Can J Psychol 1990; 44: 276-292.
89. Jones TA, Schallert T. Overgrowth and pruning of dendrites in adult rats recovering from neocortical damage. Brain Res 1992; 581: 156-160.
90. Jones TA, Schallert T. Use-dependent growth of pyramidal neurons after neocortical damage. J Neurosci 1994; 14: 2140-2152.
91. Kozlowski DA, James DC, Schallert T. Use-dependent exaggeration of neuronal injury after unilateral sensorimotor cortex lesions. J Neurosci 1996; 16: 4776-4786.
92. Coggeshall RE, Lekan HA. Methods for determining numbers of cells and synapses: a case for more uniform standards of review. J Comp Neurol 1996; 364: 6-15.
93. Abercrombie M. Estimation of nuclear population from microtome sections. Anat Rec 1946; 94: 239-247.